The Future of Palbociclib for the Treatment of Breast Cancer

Richard Finn, MD
Published Online: June 19, 2013


Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.

Currently, palbociclib is the lead indication in patients with ER-positive breast cancer, Finn says, and could become a practice-changing agent.

If the magnitude of progression-free survival benefit seen in the phase II study of this agent is seen in the phase III study, palbociclib will become the standard of care for first-line ER-positive disease, Finn notes. Palbociclib is well-tolerated, as is any anti-endocrine therapy.

If the efficacy of palbociclib can be improved without a significant increase in toxicity, the door for palbociclib would be open to other settings, Finn says. Palbociclib could be evaluated in other lines of therapy and other subtypes of breast cancer. The ultimate objective, Finn says, is to get palbociclib to early-stage disease.

Clinical Pearls



  • Finn believes palbociclib will be a practice-changing agent for the treatment of ER-positive breast cancer
  • Palbociclib demonstrated benefit to progression-free survival in this population compared with letrozole
  • In the future, palbociclib could move to other lines of therapy and subtypes of breast cancer


<<< View all coverage from the 2013 ASCO Meeting

Related Articles
Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.
Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming severe.
Prudence Francis, MD, discusses the SOFT trial, which examined suppression of ovarian function, and the impact it could have on the future treatment of women under 35 with HR+ breast cancer.
Acting two months ahead of its deadline, the FDA granted an accelerated approval to palbociclib (Ibrance) as a first-line treatment for patients with ER-positive metastatic breast cancer.
JTT Articles
Management of Hepatocellular Cancer
Mutant-Specific Epidermal Growth Factor Receptor Inhibitors
Soft Tissue Sarcomas: Emerging and Novel Concepts
External Resources

MJH Associates
AJMC
Cure
HCPLive
OncLive
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2015
Intellisphere, LLC. All Rights Reserved.